Cargando…
Modulating inflammation to reduce atherosclerotic cardiovascular events: should colchicine be part of the therapeutic regimen?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450546/ https://www.ncbi.nlm.nih.gov/pubmed/34533404 http://dx.doi.org/10.1177/17539447211042714 |
| _version_ | 1784569671906754560 |
|---|---|
| author | Jialal, Ishwarlal Vikram, Naval |
| author_facet | Jialal, Ishwarlal Vikram, Naval |
| author_sort | Jialal, Ishwarlal |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8450546 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | SAGE Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84505462021-09-21 Modulating inflammation to reduce atherosclerotic cardiovascular events: should colchicine be part of the therapeutic regimen? Jialal, Ishwarlal Vikram, Naval Ther Adv Cardiovasc Dis Editorial SAGE Publications 2021-09-17 /pmc/articles/PMC8450546/ /pubmed/34533404 http://dx.doi.org/10.1177/17539447211042714 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| spellingShingle | Editorial Jialal, Ishwarlal Vikram, Naval Modulating inflammation to reduce atherosclerotic cardiovascular events: should colchicine be part of the therapeutic regimen? |
| title | Modulating inflammation to reduce atherosclerotic cardiovascular events: should colchicine be part of the therapeutic regimen? |
| title_full | Modulating inflammation to reduce atherosclerotic cardiovascular events: should colchicine be part of the therapeutic regimen? |
| title_fullStr | Modulating inflammation to reduce atherosclerotic cardiovascular events: should colchicine be part of the therapeutic regimen? |
| title_full_unstemmed | Modulating inflammation to reduce atherosclerotic cardiovascular events: should colchicine be part of the therapeutic regimen? |
| title_short | Modulating inflammation to reduce atherosclerotic cardiovascular events: should colchicine be part of the therapeutic regimen? |
| title_sort | modulating inflammation to reduce atherosclerotic cardiovascular events: should colchicine be part of the therapeutic regimen? |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450546/ https://www.ncbi.nlm.nih.gov/pubmed/34533404 http://dx.doi.org/10.1177/17539447211042714 |
| work_keys_str_mv | AT jialalishwarlal modulatinginflammationtoreduceatheroscleroticcardiovasculareventsshouldcolchicinebepartofthetherapeuticregimen AT vikramnaval modulatinginflammationtoreduceatheroscleroticcardiovasculareventsshouldcolchicinebepartofthetherapeuticregimen |